Scores by kind of claim
Each kind of claim is scored on its own, out of 100: the share that held up, with the range it likely falls in. Fewer resolved claims give a wider range.
-
Factual claims
Statements about the present or the past, checked against the record: did they hold up?
72 63 80 -
Predictions
Statements about events outside the person's control, checked once they fell due: did they come true?
56 46 67 -
Promises
Commitments to the person's or organisation's own future action, with something to deliver: was it delivered?
Insufficient record: 0 promises resolved, 5 needed for a score.
All types combined: 65 (likely 59 to 72, high confidence), from 73 claims: 42 factual claims, 31 predictions. It mixes kinds of claim in different proportions for different people, so compare people kind by kind.
Jeremy Grantham's claims
148 claims · page 2 of 2
“In our seven-year forecast the quality segment has a full seven-percentage-point lead over the whole S&P 500, or 9% over the balance ex-quality.”
Jeremy Grantham, GMO letter author October 2009 Jeremy Grantham GMO letter 3Q 2009: Just Desserts and Markets Being Silly Again (Scribd)
This quote could not be matched word for word to the source page.
GMO's seven-year forecast has quality stocks returning 7 percentage points more than the S&P 500, or 9 points more than the non-quality remainder.
Unresolvable The public record could not settle it.
Said for an organisation they lead or work for; it counts on both records.
What would count as true or false
Judged at about October 2016, using realized annualized total returns from October 2009 to October 2016 for US quality stocks (GMO's quality definition or a comparable high-quality index) against the S&P 500 and the non-quality remainder. True: quality outperformed the S&P 500 by at least about 6.5 percentage points a year (and the remainder by roughly 8.5 points or more). Mostly true: the lead over the S&P 500 was 5 to 6.5 points a year. Mostly false: quality outperformed by more than 0 but less than 5 points a year. False: quality matched or underperformed the S&P 500.
Evidence
- SPHQ Returns by Year: Annual Total Return Table | ChartRow ChartRow
“| 2016 | $23.13 | $25.99 | | 1.9% | +14.3% |”
- SPHQ Returns by Year: Annual Total Return Table | ChartRow ChartRow
“| 2010 | $11.22 | $13.44 | | 0.7% | +20.5% |”
- S&P 500 Quality (SPHQ) — Quality Factor Explained | Originave Originave
“| 2015 | +1.64% |”
Reasoning
The evidence consists of isolated, unlabelled annual table rows for the SPHQ quality ETF (E1, E2, E3). These rows do not clearly state what each figure measures. None of them gives an annualized October 2009 to October 2016 comparison against the S&P 500 or against the non-quality remainder. The criteria cannot be applied from these fragments.
Cite this claim
Jeremy Grantham, “GMO's seven-year forecast has quality stocks returning 7 percentage points more than the S&P 500, or 9 points more than the non-quality remainder.” (said October 2009). Verdict: unresolvable. Reliability API, claim c_14162ba3cdda, method 0.1.0+28da144b. https://epistacklabs.com/claims/c_14162ba3cdda
Claims without a verdict
- Unresolvable 148
- Not yet due 17
- Own records only 29
- Not researched 194
- Not checkable 543
Is a verdict here wrong, or do you speak for Jeremy Grantham? Reply on the claim's own page, with the form at its foot (how replies work). Verdicts are made automatically; how verdicts and scores are made.